Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
581-600 of 3,900 trials

Long-Term Follow-Up for Gene-Modified T Cell Treatment

We are monitoring patients treated with gene-modified T cells to assess any delayed side effects and the long-term effectiveness of the treatment. This study also looks at the health of younger patients who received this therapy.

Malignant Lymphoid Neoplasm>2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineOncology

Lumbar Spinal Surgery: Erector Spinae Plane Block

We are studying whether a specific pain management technique can reduce the need for morphine after lumbar spinal surgery. We will also look at recovery quality and any complications related to the procedure.

Patients Undergoing Lumbar ArthrodesisMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineOrthopedics and TraumatologyOtolaryngology

Heart Procedure: Protamine Administration Study

We are comparing routine versus selective use of protamine during transcatheter aortic valve implantation to see which method better reduces bleeding and death risks after the procedure.

Aortic Stenosis≤3 monthsConfirmation phase (III)Monitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Community-Acquired Pneumonia: Customized Antibiotic Duration Study

We are investigating whether a new strategy for shortening antibiotic treatment is as effective as standard care for hospitalized patients with pneumonia. This study aims to improve patient outcomes while reducing unnecessary antibiotic use.

Community-acquired Pneumonia>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesInternal MedicinePulmonology

Prostate Cancer: AZD5305 Treatment Study

We are studying whether AZD5305, combined with standard hormonal treatments, can improve outcomes for men with metastatic castration-sensitive prostate cancer. This trial compares the new treatment to a placebo to assess its effectiveness.

Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteOncologyUrology

Autoimmune Encephalitis: Satralizumab Study

We are testing the effectiveness and safety of satralizumab in patients with NMDAR or LGI1 mediated autoimmune encephalitis. The study aims to see if it improves disability and reduces symptoms compared to a placebo.

Autoimmune Encephalitis>2 yearsConfirmation phase (III)Post-Trial Drug AccessPartially RemoteNeurologyRheumatology

Urothelial Cancer: BT8009 Treatment Study

We are investigating whether the new drug BT8009, alone or with pembrolizumab, can help patients with advanced urothelial cancer live longer and respond better than standard chemotherapy.

Locally Advanced or Metastatic Urothelial Cancer>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyUrology

Eosinophilic Granulomatosis With Polyangiitis: NS-229 Study

We are testing a new treatment, NS-229, to see if it helps patients with Eosinophilic Granulomatosis With Polyangiitis achieve remission better than a placebo. The study will also look at any side effects and the time until symptoms worsen.

Eosinophilic Granulomatosis with Polyangiitis6-12 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInfectious DiseasesRheumatology

Neuroblastoma: ABTL0812 Treatment for Children

We are testing a new drug, ABTL0812, in children with relapsed or refractory neuroblastoma and other solid tumors. The study aims to find the best dose and evaluate its safety and effectiveness when used alone or with other therapies.

Relapsed/Refractory Neuroblastoma>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesOncologyPediatrics

Small Cell Lung Cancer: BI 764532 Treatment Study

We are testing different doses of BI 764532 in patients with relapsed small cell lung cancer and other neuroendocrine cancers. The goal is to see if this treatment can help improve outcomes for those who have not responded to prior therapies.

Small Cell Lung CancerNeuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Advanced Solid Tumors: Rezatapopt Treatment Study

We are evaluating a new treatment for patients with advanced solid tumors that have a specific genetic mutation. The study aims to understand its effectiveness and safety, as well as how it affects quality of life.

Locally Advanced or Metastatic Solid Tumors with TP53 Y220C MutationSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesPartially RemoteOncology

Advanced Solid Tumors: [68Ga]Ga-DPI-4452 and [177Lu]Lu-DPI-4452 Study

We are studying the safety and effectiveness of two new treatments for patients with advanced solid tumors that cannot be removed by surgery. This trial also looks at how well these treatments can help in imaging the tumors.

Colorectal CancerDuctal Adenocarcinoma of PancreasClear Cell Renal Cell Carcinoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncology

Cancer Treatment Continuation Study

We are offering ongoing treatment for cancer patients who participated in earlier studies. This study checks the safety of the therapy while ensuring patients have access to their treatment.

Cancer Treatment Continuation>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Glofitamab for Pediatric B-Cell Non-Hodgkin Lymphoma

We are studying the safety and effectiveness of glofitamab alone and with other treatments for children and young adults with relapsed or refractory B-cell non-Hodgkin lymphoma. This research aims to find better options for managing this challenging cancer.

B-cell Non-Hodgkin's Lymphoma6-12 monthsSafety phase (I)Efficacy phase (II)No PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Elranatamab Treatment Study

We are studying the effectiveness of Elranatamab for patients with relapsed or refractory multiple myeloma who have already been treated with three different drug classes. This trial aims to see if it can help achieve better disease control.

Multiple Myeloma>2 yearsEfficacy phase (II)11-15 visitsNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Diabetic Foot Ulcers: Plasma Rich in Growth Factors Treatment

We are studying whether Plasma Rich in Growth Factors can help heal foot ulcers in diabetic patients better than standard treatments. This trial aims to improve healing outcomes for those with peripheral arterial disease.

Foot Ulcers in Diabetic Patients3-6 monthsMonitoring phase (IV)≤5 visitsNo PlaceboInvestigational MedicinesDermatologyEndocrinology

Montelukast for Mild-Moderate Parkinson’s Disease

We are studying whether Montelukast can slow disease progression in people with mild to moderate Parkinson’s disease. The trial also examines its effects on symptoms and potential side effects.

Parkinson's Disease1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesNeurology

Pleural Mesothelioma: New Chemotherapy and Immunotherapy Study

We are exploring a new treatment combining chemotherapy and immunotherapy for patients with inoperable pleural mesothelioma. The study will evaluate treatment completion rates, side effects, and overall quality of life.

Inoperable Pleural Mesothelioma1-2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Fetal and Neonatal Alloimmune Thrombocytopenia: Nipocalimab Study

We are testing nipocalimab in pregnant individuals at risk of FNAIT to see if it can lower the chances of severe complications for the baby. This study compares the treatment to a placebo to evaluate its effectiveness.

Neonatal Alloimmune Thrombocytopenia>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsInfectious Diseases

Advanced Non-Small Cell Lung Cancer: Zongertinib Study

We are testing whether zongertinib (BI 1810631) can improve outcomes for patients with advanced non-small cell lung cancer with HER2 mutations compared to standard treatment options.

Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology